• About
  • Subscribe
  • Advertise
  • Contact
Thursday, May 22, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home News

EssilorLuxottica owns 99.7% of GrandVision, paving way for delisting

by Myles Hume
December 13, 2021
in Business, Company updates & acquisitions, International, Local, News
Reading Time: 2 mins read
A A
EssilorLuxottica is expected to increase its retail footprint by around 7,000 stores across 40 countries.

EssilorLuxottica is expected to increase its retail footprint by around 7,000 stores across 40 countries.

Share on FacebookShare on Twitter

EssilorLuxottica has announced it now holds an almost 100% stake in GrandVision after the completion of a mandatory public offer period, opening the door to delist shares in the optical retailer on the Amsterdam Stock Exchange.

In a statement on 6 December, the Franco-Italian eyewear giant said it has completed the acceptance period for GrandVision shareholders to tender their shares, resulting in EssilorLuxottica obtaining an additional 13.06% of the outstanding GrandVision shares.

In addition to shares EssilorLuxottica secured in the original acquisition of a majority stake held by the Dutch investment firm HAL Holding, EssilorLuxottica now holds a total interest of 99.73%.

The GrandVision takeover is set to see EssilorLuxottica drastically increase its retail footprint by around 7,000 stores across 40 countries, and an additional 37,000 staff.

Although not linked to the deal, in Australia and New Zealand Luxottica operates under four retail banners: OPSM and Laubman & Pank (optical), Sunglass Hut (a dedicated sunglasses business), and Oakley (sunglasses, apparel, fashion and accessories). It has more than 600 storefronts, 300 head office employees and more than 4,500 store staff.

With EssilorLuxottica now holding more than a 95% interest in GrandVision, it revealed it now intends to delist the shares on Euronext Amsterdam “as soon as possible under the applicable rules”.

In the meantime, remaining GrandVision shareholders who have not tendered their shares during the acceptance period will have the opportunity to tender their shares under the same terms until 20 December 2021.

“These steps [to delist] are likely to have significant consequences for shareholders who do not tender their shares under the offer,” EssilorLuxottica stated.

More reading

Luxottica’s premiumisation plans

EssilorLuxottica completes GrandVision deal

Luxottica joins KeepSight; over half of optometry now registered

Tags: AcquisitionEssilorEssilorLuxotticaGrandVisionHAL HoldingLuxottica

Related Posts

Rayner, based in Worthing, UK, has grown its presence and staff numbers in Australia. Images: Rayner.

Rayner – a not-so-little disrupter in the ophthalmic industry

by Rob Mitchell
May 22, 2025

In just a few years, British company Rayner has grown its presence Down Under significantly. The company’s leaders outline the...

CR Labs' ECO7 lens follows the success of its ECO6 product. Image: CR Labs.

CR Labs launches new sustainable lens in thinner format

by Staff Writer
May 22, 2025

CR Labs has launched ECO7, its latest innovation in sustainable lens technology. The company says the new lens builds on...

The Provincial Referral Hospital of Ratanakiri that has received support from Sight For All. Image: Sight For All.

Sight For All raising funds for ophthalmic equipment in new eye clinics   

by Staff Writer
May 22, 2025

Australian not-for-profit Sight For All has teamed up with long-term supporter ZEISS, in a drive to raise funds for much-needed...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited